Outcome of Board Meeting

Ref: ADL/SE/2026-27/57 November 3, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400051 BSE CODE: 524348 NSE SYMBOL: AARTIDRUGS Dear Sir/Madam, Ref: Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sub: Audited Standalone and Consolidated Financial Results for the Quarter and half year ended September 30, 2026. We wish to inform you that the Board of Directors of the Company at its Meeting held today i.e. Tuesday, November 3, 2026, inter-alia, considered and approved the Audited Standalone and Consolidated Financial Results for the Quarter and half year ended September 30, 2026, in this regards we enclose:- i. Statement showing the Financial Results, ii. Statement of Assets and Liabilities, iii. Cash Flow Statement, iv. Auditor’s Report on the Financial Results, Further, please note that the Company has already made necessary arrangement to publish the financial results in the Newspapers as required under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Meeting of the Board of Directors commenced at 2:30 PM and concluded at 4:20 PM. Kindly take the same on record. Thanking you Yours faithfully, FOR AARTI DRUGS LIMITED RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M. No.: F12932 Corporate Office : Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, l=lD= Sion (East), Mumbai - 400 O2Z. (India) Tel.:022-2407 2249 I 24OL 9025 (30 Lines) Aarti Drugs Limited Fax.:022-2407 3462 I 2407 0144 Email : admin@aartidrugs,com website : www.aartidrugs.com Manufacturers of : Bulk Drugs & Chemicals CIN No. : 137060MH 1984PLC055433 AARTI DRUGS LIMITED oF AUolrED FiNANcIAL REsuLTs FoR THE QUARiEF Eil6E6 5oif, 3;FiEilEEi: i6tE I ? in lakhs Gxcept for EPS -TEt'irENT @zsl E4e4_4eg_______l llsYe t ar l vE tnr ir. Particularg IAudltedl I lA,,ditadl I lAuditedl I lAudlteol I 70,628 62,745 57,895 1,33,373 1,09,991 2,26,039 I Totallncome(l+ll ( ( (a b c)) ) C CPuo hrs act nh go af s e € sm a inote f i r nsia vtol es c nk tc o-o i rnn i8-s t sru a m od f8o fd inished goods, 44 1, (,8 72 45 2 38 ? , 4 (3 51, ,, 74 2 65 4 66 5 ) 36, (1 49 984 849 8 (28 6,, ,43 561 074 9 69 2, ,5 13 00 5 1,40 4,1 ,5 6 5 68 15 2 (d) w Eo mr pk l- oin y- ep er o bg ere ns es fi tsa n od x pst eo nc sk e-in-tradB 2,e83 2,6 693 54 2,4 607 14 5 1, ,3 41 77 6 4 1, ,8 20 83 3 9 2, ,6 62 37 8 ( (e 0) F Di en pa rn e@ cia t@ ions ts and amortisation oxpense 11 2, 5 R7 I1 R it1 ,5 o2 n1 q '1,355 3,0s2 2.582 s,564 (g) Other expenses Total exp€nses (lV) ss 771 belore ex6ptional items and tax (lll - lV) 7,673 6,9 209 94 5,578 14,6 26 46 9 1 Ie8, ,1 r3 r1 Profit before tax (V - Vl) 7,673 6,785 6 578 14,458 I VIII Tax P E rox vp ise in os ne fs o r; taxation - Curent 1,750 1,600 '1,200 3,350 t3" 8r5l0i' IX ProP fitr o /v (is Li oo sn s ) lo for rd te hf ee r Yre ed a- rtE a (a x Vr al li t le i or - n VY le lla )r Total tax expenses 51 ,, 791 0 65 55 8 51 ,, 07'1 800 500 41, ,42 100 700 8 103 ,, 862 505 355 91, ,04 060 410 2 161 ,, 92 20 28 x Other Complehensive lncom€ Item that wlll not to bo Bclassifled to statsmont of Proflt and Lo88 (31 ) 334 air valug changes on lnvestments, :,, 1u, currency translation reserye . Fair valut € ax c hr ae nl g;t ein s g o nto I nit vo em sts m t eh na tst ,will not be reclassifled to profit or loss 4 4 13 : 247 I CO oth me pr r eC ho em nsp ivr ee h lns cn os mlv ee fl on rc to hem Y,n ee art (lX+X) 5,7l2 47 1l 5,08s 4,178 ,0,826 9,042 17,169 lrerag" numoer ot "quity shares used lor @mputing 6arning per sharo 9,127 9,127 s,127 9,',t27 9,127 9,127 5,768 5,185 4'1:8 10,853 ",y, 16,922 Non- Controllino lnterest Total Compr€hensive lnome attributable to : u,rl, 5,0-85 4r:8 1 0,826 e'0:2 1 7,169 Owner o, the ComPanY Non- Controlling lnter€st 5.57 ,t.t.89 I 9.91 Notes 3 4 C Sto am tup toa rn y y Ah uas d io ton cly ho an ve e b eu rs ii en des s o us te g ium de itn t oli . ts h ep ah ba orm vea c fie nu at ni€ls c' ial results for the quarter ended 3oth September,2o26 and have exprossed unmodified audit opinion' 5 Figures lor the previous Quartsr have be€n rsgrouped or r8arrangad wher€ver necessary' 6 f,f"ii*"il-t""f, g*nange ot tnOia Limited ffi.nseindia.com for the b8nefit of the shareholders and investors' FOTAARTI DRUGS LIMITfED fi Plac Mumbai Date: 3rd Novembei 2026 Regd. Office : Plot No. N-198, MIDC, Tarapur, Tal-Palghar, Dist.Palghar - 401 506,(MH) Corporate Office : Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, I= lI = Sion (East), Mumbai - 4OO 022. (India) Tel.:022-2407 2249 I 24Ot 9025 (30 Lines) Aarti Drugs Limited Fax.:022-2407 3462 I 2407 0t44 Email : admin@aartidrugs.com website: www.aartidrugs.com Manufacturers of : Bulk Drugs & Chemicals CIN No. :137060MH1984P1C055433 AARTI DRUGS LIMITED STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDEO 3oth SEPTEMBER'2026 ( a ln lakhs excoptfor EPS) Consolidated Quarter Ended Period End€d Year Ended tr. PailcularE 30th Sept 2026 3oth Jun 2026 30th Sept 2025 3oth Sept 2026 30th Sept 2025 31st Mar 2026 lAudiledl {Audited} (Audited) lAudiled) (Audited) Revenue from opomtions 82,624 70,278 65,279 1,52,903 1,24,330 2,56,531 Other in@mo Totallncome(l+ll) 82_" 8q 79 70.358 91 65.288 1,53,23 33 86 '1,24, 2.56.770 Expensss : (a) Cost of materials @nsum€d 47,7s? 46,935 38,506 94,609 74,231 1,50,401 (b) Purchase of stock-in-trade 3,313 2,138 3,064 5.452 5,926 1 1,508 (c) Changss in invontori6s of finished goods, (1,141. (6,313) (741 17,454 (1,98e) (37) work-in-progress and stock]n-trado (d) Employee bBn8lits Expenso 3.713 3,651 3,307 7,364 6,387 12,932 (o) Financ costs 963 770 1,885 1,627 3,371 (0 D8precialion 8nd amortisation expense 1,900 1,846 1,626 3,746 3,098 6,697 (g) Other oxp€nsos 14.047 12.714 29 516 23 S3S Total expsnses (lV) 63,226 59.247 1,35.'t 1,'13,218 2,35,680 Profit beforo oxcptional ilems and tax (lll - lV) 10,928 7,132 6,041 't8)061 11,162 21,090 Excptional items 209 209 vI Profit beforB tax (V - Vl) 1 0,928 6,924 6,041 17,852 11,162 21,090 vilt Tax P E rox vp is8 in os no fs o r: taxation - Curent 2,488 1,806 1,362 4,294 2,397 4,455 - Earlier Yoar (1,489) (3 127" Provision tor dofered taxation 163 105 163 268 331 269 Total tax expenses (Vlll) 2,651 '!,91 1 1,s25 4,562 1,239 1,596 IX Profit / (Loss) for the Year ( Vll - Vlll ) 8,277 5,013 4,516 I 3,290 9,9'13 't9,494 Other Comprehensive lncome Itsm that wlll not to be Ecla3siflod to statement of Prollt and Lo88 Fair value chanoes on lnvestments, (31 ) !'' , 334 Remeasurement ot defined ben€fit Liabiliy/Assets, 132. Foreign cursncy translation reserue Qa) 6 (14) lncome tax relatlng io ltems that wlll not be Bclasslflod to proflt or losE Fair value changes on lnvestmonts, 4 4 (48 R€moasuremBnt of d€fined bsnefit Liabiliy/Assets, 13 xl TT oo tt aa ll CO oth mo pr r eC ho em nsp ir ve eh s lnn ca ol mve e ll on rc to hm e o Y, en ao rt (lX+X) 8,2t 34 07t 5,0196 n,i* 13,2{4 41 9 ) 9,9211 4 19,83 12 40 xI Weighted averege number ol equity shares used for omputing earning per share (ra6 value of Rs.10 €ech) 9,127 9,127 s,127 s,127 9,127 9,127 OPr wof nit 6 ra t otr f ib thu at a Cbl o8 m to p s: ny 8,294 5,O17 4,528 '13,311 9,919 19,492 Non- Controlling lntBr€st (17) (4.42\ (11.911 121.57J (s.68) 2.03 T Oo wta nl eC r o om t tp hBre h Co on ms piv ae n yln@me attributable to : 8,248 5,023 4,528 13,271 9,929 1 9,809 Non- Controlling lnterest (18) (4.12) (1 1.911 \22.29], (5.11) 4.63 xilt Eamino oer oouitv share ( in Rs.) (not annualised) 5.49 4,9 14.56 't0.86 21.36 Dilut6d 9.07 5.49 4.95 ,t4. '10.86 21.36 Notes subsrdrary namely Phama Go SpA., Triphama Chile SpA 4 Company has only one business segm€nt i.e. pharmaceutiels. 5 Statutory Auditors have caried out audit of th6 abovo financial results [Showing first 8,000 characters — download PDF for full document]